[email protected] +357 96 030922 Contact Us | FAQ |
Advanced search

Pharmaceuticals Market Research Reports & Industry Analysis

Publications found: 36,694
Sort by:

DNA Topoisomerase II (EC 5.99.1.3) - Drugs in Development, 2021

 US$ 3,000.00

DNA Topoisomerase II (EC 5.99.1.3) - Drugs in Development, 2021 SUMMARY DNA Topoisomerase II (EC 5.99.1.3) - Drugs in Development, 2021 provides in depth analysis on DNA Topoisomerase II (EC 5.99.1.3)...

April 2021 130 pages

DNA Topoisomerase IV (EC 5.99.1.3) - Drugs in Development, 2021

 US$ 3,000.00

DNA Topoisomerase IV (EC 5.99.1.3) - Drugs in Development, 2021 SUMMARY DNA Topoisomerase IV (EC 5.99.1.3) - Drugs in Development, 2021 provides in depth analysis on DNA Topoisomerase IV (EC 5.99.1.3)...

April 2021 80 pages

Double Homeobox Protein 4 (Double Homeobox Protein 10 or DUX4) - Drugs in Development, 2021

 US$ 3,000.00

Double Homeobox Protein 4 (Double Homeobox Protein 10 or DUX4) - Drugs in Development, 2021 SUMMARY Double Homeobox Protein 4 (Double Homeobox Protein 10 or DUX4) - Drugs in Development, 2021 provides...

April 2021 35 pages

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) (Central Nervous System) - Drugs in Development, 2021

 US$ 2,000.00

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) (Central Nervous System) - Drugs in Development, 2021 SUMMARY Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) (Central Nervous System) - D...

April 2021 65 pages

Drug-Induced Dyskinesia (Central Nervous System) - Drugs in Development, 2021

 US$ 2,000.00

Drug-Induced Dyskinesia (Central Nervous System) - Drugs in Development, 2021 SUMMARY Drug-Induced Dyskinesia (Central Nervous System) - Drugs in Development, 2021 provides an overview of the Drug-Ind...

April 2021 50 pages

Drug Toxicity (Toxicology) - Drugs in Development, 2021

 US$ 2,000.00

Drug Toxicity (Toxicology) - Drugs in Development, 2021 SUMMARY Drug Toxicity (Toxicology) - Drugs in Development, 2021 provides an overview of the Drug Toxicity pipeline landscape. The report provide...

April 2021 45 pages

Dry (Atrophic) Macular Degeneration (Ophthalmology) - Drugs in Development, 2021

 US$ 2,000.00

Dry (Atrophic) Macular Degeneration (Ophthalmology) - Drugs in Development, 2021 SUMMARY Dry (Atrophic) Macular Degeneration (Ophthalmology) - Drugs in Development, 2021 provides an overview of the Dr...

April 2021 110 pages

Dual Specificity Mitogen Activated Protein Kinase Kinase 1 (ERK Activator Kinase 1 or MAPK/ERK Kinase 1 or MAP2K1 or EC 2.7.12.2) - Drugs in Development, 2021

 US$ 3,000.00

Dual Specificity Mitogen Activated Protein Kinase Kinase 1 (ERK Activator Kinase 1 or MAPK/ERK Kinase 1 or MAP2K1 or EC 2.7.12.2) - Drugs in Development, 2021 SUMMARY Dual Specificity Mitogen Activate...

April 2021 60 pages

Dual Specificity Mitogen Activated Protein Kinase Kinase 2 (ERK Activator Kinase 2 or MAPK/ERK Kinase 2 or MAP2K2 or EC 2.7.12.2) - Drugs in Development, 2021

 US$ 3,000.00

Dual Specificity Mitogen Activated Protein Kinase Kinase 2 (ERK Activator Kinase 2 or MAPK/ERK Kinase 2 or MAP2K2 or EC 2.7.12.2) - Drugs in Development, 2021 SUMMARY Dual Specificity Mitogen Activate...

April 2021 55 pages

Ductal Carcinoma In Situ (Oncology) - Drugs in Development, 2021

 US$ 2,000.00

Ductal Carcinoma In Situ (Oncology) - Drugs in Development, 2021 SUMMARY Ductal Carcinoma In Situ (Oncology) - Drugs in Development, 2021 provides an overview of the Ductal Carcinoma In Situ pipeline...

April 2021 30 pages

Duodenal Ulcer (Gastrointestinal) - Drugs in Development, 2021

 US$ 2,000.00

Duodenal Ulcer (Gastrointestinal) - Drugs in Development, 2021 SUMMARY Duodenal Ulcer (Gastrointestinal) - Drugs in Development, 2021 provides an overview of the Duodenal Ulcer pipeline landscape. The...

April 2021 40 pages

Dystonia (Central Nervous System) - Drugs in Development, 2021

 US$ 2,000.00

Dystonia (Central Nervous System) - Drugs in Development, 2021 SUMMARY Dystonia (Central Nervous System) - Drugs in Development, 2021 provides an overview of the Dystonia pipeline landscape. The repor...

April 2021 35 pages

Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 1 (Membrane Component Chromosome 6 Surface Marker 1 or Phosphodiesterase I/Nucleotide Pyrophosphatase 1 or Plasma Cell Membrane Glycoprotein PC1 or ENPP1 or EC 3.1.4.1 or EC 3.6.1.9) - Drugs in Development, 2021

 US$ 3,000.00

Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 1 (Membrane Component Chromosome 6 Surface Marker 1 or Phosphodiesterase I/Nucleotide Pyrophosphatase 1 or Plasma Cell Membrane Glycoprot...

April 2021 30 pages

Edema (Cardiovascular) - Drugs in Development, 2021

 US$ 2,000.00

Edema (Cardiovascular) - Drugs in Development, 2021 SUMMARY Edema (Cardiovascular) - Drugs in Development, 2021 provides an overview of the Edema pipeline landscape. The report provides comprehensive...

April 2021 35 pages

Emesis (Vomiting) (Gastrointestinal) - Drugs in Development, 2021

 US$ 2,000.00

Emesis (Vomiting) (Gastrointestinal) - Drugs in Development, 2021 SUMMARY Emesis (Vomiting) (Gastrointestinal) - Drugs in Development, 2021 provides an overview of the Emesis (Vomiting) pipeline lands...

April 2021 45 pages

Emphysema (Respiratory) - Drugs in Development, 2021

 US$ 2,000.00

Emphysema (Respiratory) - Drugs in Development, 2021 SUMMARY Emphysema (Respiratory) - Drugs in Development, 2021 provides an overview of the Emphysema pipeline landscape. The report provides comprehe...

April 2021 45 pages

Endocarditis (Cardiovascular) - Drugs in Development, 2021

 US$ 2,000.00

Endocarditis (Cardiovascular) - Drugs in Development, 2021 SUMMARY Endocarditis (Cardiovascular) - Drugs in Development, 2021 provides an overview of the Endocarditis pipeline landscape. The report pr...

April 2021 30 pages

Endocrine Gland Disorders (Hormonal Disorders) - Drugs in Development, 2021

 US$ 2,000.00

Endocrine Gland Disorders (Hormonal Disorders) - Drugs in Development, 2021 SUMMARY Endocrine Gland Disorders (Hormonal Disorders) - Drugs in Development, 2021 provides an overview of the Endocrine Gl...

April 2021 50 pages

Endothelin 1 Receptor (Endothelin A Receptor or EDNRA) - Drugs in Development, 2021

 US$ 3,000.00

Endothelin 1 Receptor (Endothelin A Receptor or EDNRA) - Drugs in Development, 2021 SUMMARY Endothelin 1 Receptor (Endothelin A Receptor or EDNRA) - Drugs in Development, 2021 provides in depth analys...

April 2021 40 pages

Endothelin B Receptor (Endothelin Receptor Non Selective Type or EDNRB) - Drugs in Development, 2021

 US$ 3,000.00

Endothelin B Receptor (Endothelin Receptor Non Selective Type or EDNRB) - Drugs in Development, 2021 SUMMARY Endothelin B Receptor (Endothelin Receptor Non Selective Type or EDNRB) - Drugs in Developm...

April 2021 35 pages

Endotoxemia (Infectious Disease) - Drugs in Development, 2021

 US$ 2,000.00

Endotoxemia (Infectious Disease) - Drugs in Development, 2021 SUMMARY Endotoxemia (Infectious Disease) - Drugs in Development, 2021 provides an overview of the Endotoxemia pipeline landscape. The repo...

April 2021 35 pages

Enoyl [Acyl Carrier Protein] Reductase [NADH] FabI (NADH Dependent Enoyl ACP Reductase or Enoyl ACP Reductase or EC 1.3.1.9) - Drugs in Development, 2021

 US$ 3,000.00

Enoyl [Acyl Carrier Protein] Reductase [NADH] FabI (NADH Dependent Enoyl ACP Reductase or Enoyl ACP Reductase or EC 1.3.1.9) - Drugs in Development, 2021 SUMMARY Enoyl [Acyl Carrier Protein] Reductase...

April 2021 45 pages

Enoyl [Acyl Carrier Protein] Reductase [NADH] (FAS-II Enoyl ACP Reductase or NADH Dependent 2-Trans-Enoyl ACP Reductase or inhA or EC 1.3.1.9) - Drugs in Development, 2021

 US$ 3,000.00

Enoyl [Acyl Carrier Protein] Reductase [NADH] (FAS-II Enoyl ACP Reductase or NADH Dependent 2-Trans-Enoyl ACP Reductase or inhA or EC 1.3.1.9) - Drugs in Development, 2021 SUMMARY Enoyl [Acyl Carrier...

April 2021 30 pages

Enteritis (Gastrointestinal) - Drugs in Development, 2021

 US$ 2,000.00

Enteritis (Gastrointestinal) - Drugs in Development, 2021 SUMMARY Enteritis (Gastrointestinal) - Drugs in Development, 2021 provides an overview of the Enteritis pipeline landscape. The report provide...

April 2021 30 pages

Enterobacteriaceae Infections (Infectious Disease) - Drugs in Development, 2021

 US$ 2,000.00

Enterobacteriaceae Infections (Infectious Disease) - Drugs in Development, 2021 SUMMARY Enterobacteriaceae Infections (Infectious Disease) - Drugs in Development, 2021 provides an overview of the Ente...

April 2021 95 pages

Enterococcus Faecium Infections (Infectious Disease) - Drugs in Development, 2021

 US$ 2,000.00

Enterococcus Faecium Infections (Infectious Disease) - Drugs in Development, 2021 SUMMARY Enterococcus Faecium Infections (Infectious Disease) - Drugs in Development, 2021 provides an overview of the...

April 2021 45 pages

Enterococcus Infections (Infectious Disease) - Drugs in Development, 2021

 US$ 2,000.00

Enterococcus Infections (Infectious Disease) - Drugs in Development, 2021 SUMMARY Enterococcus Infections (Infectious Disease) - Drugs in Development, 2021 provides an overview of the Enterococcus Inf...

April 2021 45 pages

Enterovirus Infections (Infectious Disease) - Drugs in Development, 2021

 US$ 2,000.00

Enterovirus Infections (Infectious Disease) - Drugs in Development, 2021 SUMMARY Enterovirus Infections (Infectious Disease) - Drugs in Development, 2021 provides an overview of the Enterovirus Infect...

April 2021 55 pages

Envelope Protein M (Matrix Protein) - Drugs in Development, 2021

 US$ 3,000.00

Envelope Protein M (Matrix Protein) - Drugs in Development, 2021 SUMMARY Envelope Protein M (Matrix Protein) - Drugs in Development, 2021 provides in depth analysis on Envelope Protein M (Matrix Prote...

April 2021 30 pages

Ependymoma (Oncology) - Drugs in Development, 2021

 US$ 2,000.00

Ependymoma (Oncology) - Drugs in Development, 2021 SUMMARY Ependymoma (Oncology) - Drugs in Development, 2021 provides an overview of the Ependymoma pipeline landscape. The report provides comprehensi...

April 2021 55 pages

Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) - Drugs in Development, 2021

 US$ 3,000.00

Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) - Drugs in Development, 2021 SUMMARY Ephrin Type A Receptor 2 (Epithelial Cell Kinase...

April 2021 35 pages

Epidermal Growth Factor (EGF) - Drugs in Development, 2021

 US$ 3,000.00

Epidermal Growth Factor (EGF) - Drugs in Development, 2021 SUMMARY Epidermal Growth Factor (EGF) - Drugs in Development, 2021 provides in depth analysis on Epidermal Growth Factor (EGF) targeted pipel...

April 2021 35 pages

Epidermal Growth Factor Receptor (EC 2.7.10.1) - Drugs in Development, 2021

 US$ 3,000.00

Epidermal Growth Factor Receptor (EC 2.7.10.1) - Drugs in Development, 2021 SUMMARY Epidermal Growth Factor Receptor (EC 2.7.10.1) - Drugs in Development, 2021 provides in depth analysis on Epidermal...

April 2021 35 pages

Epileptic Encephalopathy (Central Nervous System) - Drugs in Development, 2021

 US$ 2,000.00

Epileptic Encephalopathy (Central Nervous System) - Drugs in Development, 2021 SUMMARY Epileptic Encephalopathy (Central Nervous System) - Drugs in Development, 2021 provides an overview of the Epilep...

April 2021 40 pages

Epithelial Ovarian Cancer (Oncology) - Drugs in Development, 2021

 US$ 2,500.00

Epithelial Ovarian Cancer (Oncology) - Drugs in Development, 2021 SUMMARY Epithelial Ovarian Cancer (Oncology) - Drugs in Development, 2021 provides an overview of the Epithelial Ovarian Cancer pipeli...

April 2021 300 pages

Epithelial Sodium Channel (ENaC or SCNN1) - Drugs in Development, 2021

 US$ 3,000.00

Epithelial Sodium Channel (ENaC or SCNN1) - Drugs in Development, 2021 SUMMARY Epithelial Sodium Channel (ENaC or SCNN1) - Drugs in Development, 2021 provides in depth analysis on Epithelial Sodium Ch...

April 2021 40 pages

Esophageal Squamous Cell Carcinoma (ESCC) (Oncology) - Drugs in Development, 2021

 US$ 2,000.00

Esophageal Squamous Cell Carcinoma (ESCC) (Oncology) - Drugs in Development, 2021 SUMMARY Esophageal Squamous Cell Carcinoma (ESCC) (Oncology) - Drugs in Development, 2021 provides an overview of the...

April 2021 110 pages

Essential Tremor (Central Nervous System) - Drugs in Development, 2021

 US$ 2,000.00

Essential Tremor (Central Nervous System) - Drugs in Development, 2021 SUMMARY Essential Tremor (Central Nervous System) - Drugs in Development, 2021 provides an overview of the Essential Tremor pipel...

April 2021 40 pages

Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Drugs in Development, 2021

 US$ 3,000.00

Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Drugs in Development, 2021 SUMMARY Estrogen Receptor (ER Alpha or Estradiol Recep...

April 2021 60 pages

Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) - Drugs in Development, 2021

 US$ 3,000.00

Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) - Drugs in Development, 2021 SUMMARY Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa...

April 2021 35 pages

Excitatory Amino Acid Transporter 2 (Glutamate/Aspartate Transporter II or Sodium Dependent Glutamate/Aspartate Transporter 2 or Solute Carrier Family 1 Member 2 or SLC1A2) - Drugs in Development, 2021

 US$ 3,000.00

Excitatory Amino Acid Transporter 2 (Glutamate/Aspartate Transporter II or Sodium Dependent Glutamate/Aspartate Transporter 2 or Solute Carrier Family 1 Member 2 or SLC1A2) - Drugs in Development, 202...

April 2021 30 pages

Exo Alpha Sialidase (Neuraminidase or Acetylneuraminidase or EC 3.2.1.18) - Drugs in Development, 2021

 US$ 3,000.00

Exo Alpha Sialidase (Neuraminidase or Acetylneuraminidase or EC 3.2.1.18) - Drugs in Development, 2021 SUMMARY Exo Alpha Sialidase (Neuraminidase or Acetylneuraminidase or EC 3.2.1.18) - Drugs in Deve...

April 2021 50 pages

Exocrine Pancreatic Insufficiency (Gastrointestinal) - Drugs in Development, 2021

 US$ 2,000.00

Exocrine Pancreatic Insufficiency (Gastrointestinal) - Drugs in Development, 2021 SUMMARY Exocrine Pancreatic Insufficiency (Gastrointestinal) - Drugs in Development, 2021 provides an overview of the...

April 2021 30 pages

Extrahepatic Bile Duct Cancer (Oncology) - Drugs in Development, 2021

 US$ 2,000.00

Extrahepatic Bile Duct Cancer (Oncology) - Drugs in Development, 2021 SUMMARY Extrahepatic Bile Duct Cancer (Oncology) - Drugs in Development, 2021 provides an overview of the Extrahepatic Bile Duct C...

April 2021 40 pages

Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma) (Oncology) - Drugs in Development, 2021

 US$ 2,000.00

Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma) (Oncology) - Drugs in Development, 2021 SUMMARY Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associate...

April 2021 60 pages

Facioscapulohumeral Muscular Dystrophy (FSHD) (Musculoskeletal Disorders) - Drugs in Development, 2021

 US$ 2,000.00

Facioscapulohumeral Muscular Dystrophy (FSHD) (Musculoskeletal Disorders) - Drugs in Development, 2021 SUMMARY Facioscapulohumeral Muscular Dystrophy (FSHD) (Musculoskeletal Disorders) - Drugs in Deve...

April 2021 40 pages

FAD-Dependent Decaprenylphosphoryl-Beta-D-Ribofuranose 2-Oxidase (Decaprenylphospho-Beta-D-Ribofuranose 2-Dehydrogenase or Decaprenylphosphoryl-Beta-D-Ribofuranose 2'-Epimerase 1 or dprE1 or EC 1.1.98.3) - Drugs in Development, 2021

 US$ 3,000.00

FAD-Dependent Decaprenylphosphoryl-Beta-D-Ribofuranose 2-Oxidase (Decaprenylphospho-Beta-D-Ribofuranose 2-Dehydrogenase or Decaprenylphosphoryl-Beta-D-Ribofuranose 2'-Epimerase 1 or dprE1 or EC 1.1.98...

April 2021 30 pages

Familial Amyloid Cardiomyopathy (Metabolic Disorders) - Drugs in Development, 2021

 US$ 2,000.00

Familial Amyloid Cardiomyopathy (Metabolic Disorders) - Drugs in Development, 2021 SUMMARY Familial Amyloid Cardiomyopathy (Metabolic Disorders) - Drugs in Development, 2021 provides an overview of th...

April 2021 30 pages

Familial Chylomicronemia (Type I Hyperlipoproteinemia) (Metabolic Disorders) - Drugs in Development, 2021

 US$ 2,000.00

Familial Chylomicronemia (Type I Hyperlipoproteinemia) (Metabolic Disorders) - Drugs in Development, 2021 SUMMARY Familial Chylomicronemia (Type I Hyperlipoproteinemia) (Metabolic Disorders) - Drugs i...

April 2021 35 pages

Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) (Metabolic Disorders) - Drugs in Development, 2021

 US$ 2,000.00

Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) (Metabolic Disorders) - Drugs in Development, 2021 SUMMARY Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) (Metabolic Disorder...

April 2021 30 pages

Filters

Clear all

Search

Categories

153
299
490
372
93
184
386
14,910
12,134
222
1,273
225
433
345
3,983
72
1,120

Publishers

2,237
1,678
72
37
1
4,083
2,049
451
220
650
292
33
4
2,631
796
123
12
81
339
120
1,132
5
6
6
23
18
40
259
30
34
6,128
13
12
142
363
8
25
84
660
8
14
8
49
197
7
2,296
266
579
2,792
7
24
44
31
54
92
7
2,538
40
34
11
22
16
38
2
4
97
4
26
50
1
214
11
120
36
21
227
32
50
27
32
42
878
54
326
51
88
92
60
37
2
14
22
2

Regions

102
85
28
27
26
26
17
14
10
9
7
7
7
7
6
5
3
3
2
2
1
1,629
258
224
198
178
117
113
104
78
73
61
53
42
42
39
36
35
33
30
30
29
29
20
20
20
19
18
18
17
15
15
15
14
13
13
13
13
13
12
12
12
12
12
11
11
11
11
11
10
10
10
9
7
6
6
5
201
260
22
21
883
256
141
68
57
34
29
6
6
6
6
5
5
4
3
3
5
5
5
4
3
2
1
1
1
1
2
2
462
29,919

Price

—

Date

—

Pages

—

Offers

44
5
1